Use of a flavonoid extract of ginkgo biloba leaves, and more specifically of a terpene-free extract, in the pharmaceutical and / or cosmetic domain and more particularly in the buccodental domain

MYPI1997005041A0Inactive Publication Date: 1998-04-25IPSEN PHARMA SAS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI1997005041
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
1996-10-25
Filing Date
1997-10-24
Publication Date
1998-04-25
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current buccodental treatments lack effective anti-elastase and anti-inflammatory agents that are free from terpenes, which are essential for addressing conditions like gingivitis without causing adverse reactions.

Method used

A terpene-free flavonoid extract of Ginkgo biloba leaves, containing 28-35% flavonoid heterosides, is used in buccodental preparations, obtained through a solvent-based extraction process with a deterpenation step using specific solvents like ethyl acetate and heptane, combined with ceramides to enhance bioavailability and activity.

Benefits of technology

The extract demonstrates significant anti-elastase and anti-inflammatory activity, reducing gingivitis and gum inflammation, as shown in clinical studies, making it suitable for pharmaceutical and cosmetic applications in the buccodental domain.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

THE INVENTION CONCERNS THE USE OF A FLAVONOID EXTRACT OF GINKGO BLOBA LEAVES, AND MORE SPECIFICALLY OF A TERPENE-FREE EXTRACT, IN THE PHARMACEUTICAL AND / OR COSMETIC DOMAIN AND MORE PATICULARLY IN THE BUCCODENTAL DOMAIN. THE INVENTION ALSO CONCERNS A BUCCODENTAL COMPOSITION CONTAINING SUCH AN EXTRACT.
Need to check novelty before this filing date? Find Prior Art

Description

USE OF A FLAVONOID EXTRACT OF GINKGO BILOBA LEAVES, . AND MORE SPECIFICALLY OF A TERPENE-FREE EXTRACT, IN THE PHARMACEUTICALAND / OR COSMETIC DOMAIN AND MORE PARTICULARLY IN THE BUCCODENTAL DOMAINThe invention concerns the use in the bucco-dental domain of a flavonoid extract of Ginkgo biloba and, more specifically, an extract which is substantially terpene-free. The invention also concerns buccodental preparations containing such an extract.A terpene-free flavonoid extract of Ginkgo biloba leaves according to the invention consists of 5 flavonoid heterosides and little or no terpene. If the extract does contain terpenes, the maximum concentration of terpenes is no more than 1%, and preferably no more than 0.5%. This extract contains between 28 and 35% of flavonoid heterosides and preferably between 28 and 32%.Such extracts are preferably obtained from the leaves of young, clipped Ginkgo biloba trees.The object of the invention is a process for preparing such an extract, a process which involves 1 0 several extraction steps from Ginkgo biloba leaf extract using solvents, and is characterised by the fact that one of the extraction steps consists of a deterpenation step, and that the solvent used is a compound with the formula RC(O)OR', in which R and R' independently represent a lower alkyl, either alone or mixed with a saturated aliphatic hydrocarbon containing at least 5 carbon atoms. The extraction step can be carried out at any stage during the process. The5 solvent used during the deterpenation step should preferably contain between 0 and 20% saturated aliphatic hydrocarbon.The extraction steps other than the deterpenation step are known in the literature, notably in patents EP 431535, EP 431536, EP 360556 and EP 324197. These patents are incorporated in the present application by reference.0 In the definitions indicated above, the expression lower alkyl preferably represents a linear or branched alkyl radical which has between 1 and 6 carbon atoms and in particular an alkyl radical which has between 1 and 4 carbon atoms, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and ieri-butyl radicals. Solvents with the formula RC(O)OR' in which the R and R' radicals represent methyl, ethyl or propyl, and notably ethyl acetate, are preferably5 used. The saturated aliphatic hydrocarbon may be chosen from amongst hexane, heptane and octane. Heptane is preferably used.λ-2Α flavonoid extract of Ginkgo biloba leaves, as defined above, exhibits anti-elastase and antiinflammatory activity on human gums. An illustration of these properties is given in the experimental section below.These properties make the Ginkgo extract as defined above suitable for pharmaceutical use. The object of the present application is the use of a flavonoid extract of Ginkgo biloba leaves, as defined above, as a medicinal product and notably as a medicinal product intended for the buccodental sphere.The object of the invention also includes a pharmaceutical composition intended notably for the treatment of the buccodental sphere and containing, as its active ingredient, a flavonoid extract of Ginkgo biloba leaves as defined above, which may be combined with a pharmaceutically acceptable vehicle.The object of the invention is more particularly an anti-elastase pharmaceutical composition containing, as an anti-elastase agent, at least an active quantity of an extract of Ginkgo as defined above. The invention has as its object more particularly an anti-inflammatory pharmaceutical composition containing, as an anti-inflammatory agent, at least an active quantity of an extract of Ginkgo as defined above.A pharmaceutical composition according to the invention contains between 0.05 and 0.6% of Ginkgo extract, and preferably between 0.1 and 0.5%. Such a preparation, may also contain at least one other agent with similar or complementary properties. A pharmaceutical composition according to the invention preferably contains Ginkgo extract as defined above combined with ceramides. Such a preparation preferably contains between 0.1 and 0.5% of Ginkgo extract, and between 0.05 and 0.3% of ceramides.A pharmaceutical composition according to the invention may take any appropriate form depending on the route of administration chosen. It may the form of a liquid such as, for example a solution, a suspension or an emulsion. It may also take the form of a gel, a spray, a toothpaste or a chewing gum. It preferably takes the form of a gel or chewing gum. In addition to the extract of Ginkgo, either alone or in combination, and an appropriate vehicle, it may contain the ingredients or adjuvants habitually used for the manufacture of such compositions.Another object of the invention is the use of a flavonoid extract of Ginkgo, as defined above, for the preparation of a pharmaceutical composition intended for the treatment of the buccodental sphere.More particularly the object of the invention is the use of a flavonoid extract of Ginkgo, as defined above, for the preparation of a pharmaceutical composition intended to inhibit elastase. Another more particular object of the invention is the use of a flavonoid extract of Ginkgo, as- 3 defined above, for the preparation of a pharmaceutical composition intended to inhibit inflammation of the buccodental sphere. Such a flavonoid extract can be used alone or in combination with another agent with similar or complementary properties depending on the intended purpose, and if necessary with an appropriate vehicle. An extract as defined above should preferably be used concomitantly with ceramides.Ceramides are sphingolipids which are present in all cell structures. They also occur in plants and particularly in wheat, rice, soya, millet and spinach. They can also be synthesised. Due to their structure, they can usefully be employed as vehicles, and considerably enhance the bioavailability of the active ingredient which they carry. The term ceramide used in the present application has the usual meaning familiar to experts in the field. Thus, the term ceramide includes all ceramides, whether of synthetic or natural origin (vegetable, animal or human) which may be substituted, for instance by a sugar as in the mono- or polyglycosylceramides.Due to the high flavonoid heteroside content, current methods suggest that an extract as defined above demonstrates anti-oxidant and anti-free radical activity. Furthermore, in view of its antiinflammatory, anti-elastase and also vasoregulating and collagene activating activity on the one hand, and the virtually total absence of terpenes in its composition, on the other, such an extract can advantageously be used in cosmetology or dermatology.Another object of the invention is a cosmetic composition intended notably for the buccodental sphere which contains a flavonoid extract of Ginkgo biloba leaves as defined above. Another object of the invention is a dermatologic composition having vasoregulating and / or collagene activity which contains a flavonoid extract of Ginkgo biloba leaves as defined above.This extract may be used either alone or combined with at least one other agent with similar or complementary activity, and possibly with an appropriate vehicle. The Ginkgo extract is preferably used in combination with ceramides. A cosmetic or a dermatologic preparation according to the invention may contain between 0.05 and 0.6% of Ginkgo extract as defined above, and between 0.05 and 0.3% of ceramides. Such a preparation may take any appropriate form in this type of application such as creams, emulsions, make-up products, lipsticks, mils, gels, oils or lotions. In addition to Ginkgo extract, alone of combined, and an appropriate vehicle, it may contain the ingredients or adjuvants usually used in the preparation of such products.Another object of the invention is the use of a flavonoid extract of Ginkgo biloba as defined above for the cosmetic treatment of disorders of buccodental sphere and notably of gingivitis.The following examples are given to illustrate the invention and must in no way be considered to limit the scope of the invention.- 4Experimental partProcess for the preparation of a flavonoid extractThe leaves of Ginkgo biloba are extracted with 6 to 12 parts (preferably 8) of water containing 60% acetone at 50-60% and the solution is concentrated in order to reduce the percentage of acetone to less than 3%. This solution is cooled and the lipids are eliminated by decantation. The aqueous solution is extracted with 2 to 5 parts of ethyl acetate containing 0 to 20% of heptane. The resulting solution is extracted with a minimum quantity of a mixture of acetone / butanol (percentage of acetone 0 to 15%) in the presence of ammonium sulphate. The organic phase is concentrated; after adding ethanol, the solution is concentrated once more. After diluting again with ethanol, the resulting solution is concentrated, dried and finally crushed in order to recover the flavonoid extract in the form of a uniform powder.Study of the anti-elastase and anti-inflammatory activity of a substantially terpene free, extract of a flavonoid extract of Ginkgo biloba.- Ex-vivo study of anti-elastase activityThe purpose of this study was therefore to investigate the anti-elastase activity of an extract as defined above, either alone or combined with ceramides. This activity was evaluated using sections of human gums.The ceramides used, of vegetable origin, were obtained using a process as described in patent FR 2676936 incorporated by reference, a process which includes the extraction of wheat, using a polar extraction solvent followed by recrystallisation in an organic solvent. They consist essentially of glycosylceramides and ceramides.To do this, the matrix of elastin fibres was subjected to human leukocytic elastase (HLE), with or without an anti-elastase substance. Elastin fibres which were still present after exposure to the enzymatic activity are stained by (+) catechin.Frozen 8 pm slices were prepared from 5 specimens obtained from biopsies of normal buccal mucosa, taken during dental extractions.ProtocolFirstly, the concentration of human leukocytic elastase (HLE) required to destroy the elastin fibres is determined. The leukocytic elastase is applied to the skin sections for two hours at room temperature and in a moist atmosphere; after fixing in acetone and dehydrating in ethanol at 70°C, any remaining elastin fibres were stained with (+) catechin. Total destruction of the elastin fibres was obtained by exposure to 10 μΜ / ml human leukocytic elastase.-5In order to demonstrate whether the substances were bound to the enzyme, similar quantities of the substances, in the form of an emulsion, and 10 μΜ / ml of human leukocytic elastase were applied simultaneously to the slices for two hours at room temperature. The anti-elastase activity of the substances was compared to that of PMSF, a potent elastase inhibitor.Morphometric quantification — using image analysis — provided data which are reported in Table 1, below.Table 1: percentage of elastin fibres remaining after exposure to human leukocytic elastase in the presence of Ginkgo extract either alone or combined with ceramidesupper corium middle corium lower corium HLE alone HLE + PMSF 0 25 0 55 0 70 Ginkgo extract (%) + Ceramide (%) 0 0.1 0 0 27.65 0 0.2 0 0 22.50 0.1 0 0 0 13.85 0.3 0 0 0 33 0.5 0 2.5 31.85 61.20 0.1 0.1 0 0 24.5 0.3 0.1 0 17.6 23 0.5 0.1 56.7 47 65 0.1 0.2 0 0 15.2 0.3 0.2 0 19 30 0.5 0.2 70 53.2 80- Study of the anti-inflammatory activityThe preparation investigated in this study took the form of a gel containing 0.5% of Ginkgo extract as defined above and 0.1% of ceramide of plant origin, as defined in the study of antielastase activity.-6The study was carried out in 20 patients suffering from benign, moderate tartar-induced gingivitis. The patients applied the gel to their gingival mucosae twice daily for one month. The clinical assessment of the state of the gums was carried out on days DO and D28 using a scoring system. The main assessment criteria were the assessment of erythema and gingivitis. The anti-inflammatory action of the treatment should have resulted in a reduction in the erythema and a reduction in the gingivitis.Clinically, erythema takes the form of an erythematous appearance (redness) of the gum and a high gingivitis score. The restoration of the normal state of the gum, the reduction of the erythema and of the severity of the gingivitis and its extent provided the clinical demonstration of anti-inflammatory activity.The secondary criteria consisted of the assessment of the spontaneous pain and that induced by chewing and of bleeding (extent and location).Interpretation of the criteriaThe three main criteria reflecting the degree of the inflammatory activity, gingivitis, colour of the gums and location of the area affected, were assigned a score of 2 in the expression of the results.The index spontaneous pain, pain induced by chewing and papillary bleeding (extent and location), were assigned a score of 1 in the expression of the results.The scale used to score the gingivitis was as follows:(0) if it is scored 0: normal gums, no inflammation, no colour change, no bleeding;(2) if it is scored 1: small area of gingivitis, slight inflammation, slight deterioration in the gum surface, no bleeding;(4) if it is scored 2: moderately widespread gingivitis, moderate inflammation, erythema, oedema, bleeding induced by probing or after applying pressure;(6) if it is scored 3: very widespread gingivitis, severe inflammation, considerable erythema, oedema, tendency towards spontaneous bleeding, ulceration.The scale used to evaluate the colour of the gum was as follows:(0) normal (2) mild erythema (4) moderate erythema (6) severe erythema- Topographical evaluation of gum colourSix sectors were defined; RT, FT, LT, RB, FB and LB (where F, T, L, R and L indicate Front, Top, Bottom, Right and Left respectively).(0) No sector affected (2) One sector affected (4) Two sectors affected (6) Three sectors affected (8) More than three sectors affected- The following scale was used to evaluate the papillary bleeding (Engelberger et al., 1993) (0) if it was scored 0: no bleeding 10 to 30 seconds after probing (2) if it was scored 1: light bleeding (fine streak of blood) (4) if it was scored 2: moderate bleeding (6) if it was scored 3: intense bleeding- Topographical evaluation of papillary bleeding (0) No sector affected (1) One sector affected (2) Two sectors affected (3) Three sectors affected (4) More than three sectors affected- The changes in the spontaneous pain and pain induced by chewing factors were evaluated using a visual scale on DO and D28:(0) if pain was absent or mild (measured between 0 and 2.5 cm on the visual scale) (1) if pain was moderate (measured between 2.5 and 5 cm on the visual scale) (2) if pain was considerable (measured between 5 and 7.5 cm on the visual scale) (3) if pain was severe (measured between 7.5 and 10 cm on the visual scale)- A global index was then calculated as the sum of the various scores:- a return to normal is scored 0- maximum seriousness is scored 33 The findings are shown in Table 2 below.- 8 Table 2Day DO Day D28 Evaluation of gingivitis 3.5 ± 1 1.0 ± 1.2 (p<0.05) Evaluation of gum colour (erythema) 4.0 ± 1.4 1.1 ± 1.45 (p<0.05) Topography of gingival erythema 4.80 ± 1.7 1.6 ± 11.8 (p<0.05) Evaluation of papillary bleeding 0.85 ± 0.8 0.1 ± 0.43 (p<0.05) Topography of papillary bleeding 1.20 ± 1.12 0.1 ± 0.43 (p<0.05) Evaluation of spontaneous pain 1.35 ± 1.2 0 (p<0.05) Evaluation of pain induced by chewing 1.10 ± 1.17 0 (p<0.05) Global score 16.80 ± 4.8 3.9 ± 4.6 (p<0.05)This study conducted in 20 patients suffering from tartar-induced gingivitis demonstrated the 5 anti-inflammatory activity of an extract of Ginkgo as defined above, combined with ceramides of plant origin.This anti-inflammatory activity was demonstrated in a clinically significant manner by the disappearance of the gingivitis and gingival erythema in 11 out of 20 cases and by an improvement in another 8 cases.A significant improvement was observed in the papillary bleeding index and the complete disappearance, in all cases of, gum pain (both spontaneous and induced by chewing).

Claims

CLAIMS:

1. A pharmaceutical composition intended for the treatment of the dentibuceal sphere and containing as active ingredient a sufficient amount of a flavonoid extract of ginkgo biloba leaves comprising 28 to 35 % by weight of flavonoid glycosides substantially free of terpenes said extraction being several stages of extraction with solvents with one extraction being a deterpenation extraction with a compound of the formula R-C(O)-O-R’ wherein R and R’ are independently lower alkyl optionally admixed with a saturated aliphatic hydrocarbon of at least 5 carbon atoms to treat affections thereof and an inert carrier.

2. A composition of claim 1, characterized in that it exhibits and anti-elastasic activity.

3. A composition of claim 1, characterized in that it exhibits an antiinflammatory activity.

4. A cosmetic composition intended for the dentibuceal sphere and containing a flavonoid extract of ginkgo biloba leaves 28 to 35 % by weight of flavonoid glycosides substantially free of terpenes said extraction being several stages of extraction with solvents with one extraction being a deterpenation extraction with a compound of the formula R-C(O)-O-R’ wherein R and R’ are independently lower alkyl optionally admixed with a saturated aliphatic hydrocarbon of at least 5 carbon atoms to treat affections thereof.

5. A composition of claim 1 containing 28 to 32 % by weight of flavonoid -10glycosides.

6. A composition of claim 1 wherein the extract contains a maximum of 1 % by weight or terpenes.

7. A composition of claim 1 wherein the extract contains a maximum of 0.5 % by weight of terpenes.

8. A composition of claim 1 containing 0.05 to 0.6 % by weight of said 10 extract.

9. A composition of claim 1 also containing 0.05 to 0.3 % by weight of ceramides. 15 10. A composition of claim 1 in the form of a gel or chewing gum.